From: Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study
 | N | % | Person-Years of Follow-up | Deaths per 1,000 Person Years |
---|---|---|---|---|
Sex | Â | Â | Â | Â |
   Female | 1,992 | 37.4 | 17,221 | 9.4 |
   Male | 3,328 | 62.6 | 28,587 | 11.8 |
Age Group, years | Â | Â | Â | Â |
   35-39 | 25 | 0.5 | 214 | 9.3 |
   40-49 | 1,708 | 32.1 | 14,995 | 4.7 |
   50-59 | 2,436 | 45.8 | 20,954 | 11.4 |
   60+ | 1,151 | 21.6 | 9,644 | 19.7 |
Body Mass Index, kg/m2 | Â | Â | Â | Â |
   < 25 | 2,536 | 47.7 | 21,849 | 10.7 |
   25- 30 | 2,098 | 39.4 | 18,075 | 10.6 |
   > = 30 | 686 | 12.9 | 5,884 | 12.7 |
Education (years) | Â | Â | Â | Â |
   < 12 | 639 | 12.0 | 5,496 | 14.0 |
   12 | 1,595 | 30.0 | 13,735 | 11.5 |
   > 12 | 3,086 | 58.0 | 26,577 | 10.0 |
Race | Â | Â | Â | Â |
   White | 5,136 | 96.5 | 44,226 | 10.6 |
   Non-White | 184 | 3.5 | 1,582 | 19.6 |
Smoking Status | Â | Â | Â | Â |
   Former | 1,386 | 26.1 | 12,063 | 7.5 |
   Intermittent | 627 | 11.8 | 5,403 | 10.2 |
   Current | 3,307 | 62.2 | 28,342 | 12.5 |
Randomization Group | Â | Â | Â | Â |
   Intervention, Ipratroprium | 1,791 | 33.7 | 15,470 | 9.6 |
   Intervention, Placebo | 1,770 | 33.3 | 15,271 | 10.5 |
   Control | 1,759 | 33.1 | 15,067 | 12.7 |
Stage (pre-bronchodilator)* | Â | Â | Â | Â |
   Stage 3 or 4 | 341 | 6.4 | 2,831 | 21.5 |
   Stage 2 | 3,587 | 67.4 | 30,875 | 11.3 |
   Stage 1 | 995 | 18.7 | 8,674 | 7.3 |
   Restricted | 92 | 1.7 | 768 | 15.6 |
   Normal | 305 | 5.7 | 2,659 | 5.6 |
Stage (post-bronchodilator)* | Â | Â | Â | Â |
   Stage 3 or 4 | 183 | 3.4 | 1,475 | 29.8 |
   Stage 2 | 3,048 | 57.3 | 26,237 | 12.0 |
   Stage 1 | 1,242 | 23.3 | 10,775 | 7.2 |
   Restricted | 126 | 2.4 | 1,059 | 13.2 |
   Normal | 721 | 13.6 | 6,262 | 7.8 |